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Age-related macular degeneration (AMD) is the leading cause of severe visual loss and blindness over the age of 50 in developed
countries. Vascular endothelial growth factor (VEGF) is considered as a critical molecule in the pathogenesis of choroidal
neovascularization (CNV), which characterizes the neovascular AMD. Anti-VEGF agents are considered the most promising
way of eﬀectively inhibition of the neovascular AMD process. VEGF is a heparin-binding glycoprotein with potent angiogenic,
mitogenic and vascular permeability-enhancing activities speciﬁc for endothelial cells. Two anti-VEGF agents have been approved
by the US Food and Drug Administration (FDA) for the treatment of neovascular AMD. Pegaptanib sodium, which is an aptamer
and ranibizumab, which is a monoclonal antibody fragment. Another humanized monoclonal antibody is currently oﬀ-label
used, bevacizumab. This paper aims to discuss in details the eﬀectiveness, the eﬃcacy and safety of these three anti-VEGF agents.
New anti-VEGF compounds which are recently investigated for their clinical usage (VEGF-trap, small interfering RNA) are also
discussed for their promising outcomes.
1.Introduction
Vascular endothelial growth factor (VEGF) is a critical mol-
ecule involved in the pathogenesis of neovascular eye dis-
eases such as neovascular age-related macular degeneration
(AMD), proliferative diabetic retinopathy (PDR), diabetic
macular edema (DME), retinal vein occlusion (RVO), and
retinopathy of prematurity (ROP) [1].
Anti-VEGF-based therapies which are currently under
investigation for their eﬃcacy and safety in these neo-
vascular diseases include an aptamer, pegaptanib sodium,
ranibizumab and bevacizumab (VEGF-speciﬁc antibodies),
the immunoglobulin G (IgG)-VEGF receptor fusion protein,
VEGF trap, and the small interfering RNA (siRNA), bevasir-
anib [1].
Purpose of this paper is to summarize the current lit-
erature regarding the eﬀectiveness of current anti-VEGF
treatment for neovascular AMD.
2.VascularEndothelialGrowthFactor(VEGF)
Theadventofantivascularendothelialgrowthfactor(VEGF)
treatments marks a major advancement in the treatment of
angiogenic eye disease [1].
VEGF was isolated in the 1980s [2] initially as a
tumour-derived factor that increased vascular permeability
[3] and subsequently as an endothelial mitogen. It is a
homodimeric glycoprotein and is a growth factor speciﬁc
for endothelial cells [4]. It is a critical regulator of vascu-
logenesis and angiogenesis, as well as a potent inducer of
vascular permeability [5]. It is a member of the platelet-
derived growth factor (PDGF) family [6]. VEGF levels are
increased by hypoxia, rendering VEGF-driven angiogenesis a
hallmark response to low oxygen tension [7]. Its expression
is upregulated by a number of growth factors, including
epidermal growth factor, transforming growth factor-α and
-β, keratinocyte growth factor, insulin-like growth factor-I,
ﬁbroblast growth factor, and platelet-derived growth factor,2 Journal of Ophthalmology
such that a variety of local interactions can modulate local
VEGF concentrations [6, 8].
Three receptor tyrosine kinases have been identiﬁed
for VEGF: VEGF receptor (VEGFR) 1 (fms-like tyrosine
kinase-1) has both positive and negative angiogenic eﬀects;
VEGFFR2 (fetal liver kinase-1 and kinase insert domain-
containing receptor) is the primary mediator of the mito-
genic,angiogenic,andvascularpermeabilityeﬀectsofVEGF-
A; VEGFFR3 mediates the angiogenic eﬀects on lymphatic
vessels [4, 9].
The VEGF gene family consists of VEGF-A, VEGF-
B, VEGF-C, VEGF-D, and placental growth factor (PlGF),
which have diﬀerent binding aﬃnities for the three VEGF
receptors [10, 11]. VEGF-A, which is the best studied,
has been most strongly associated with angiogenesis and
thus consists the target of most anti-VEGF treatments
[12, 13]. VEGF-A signals through two receptor tyrosine
kinases, VEGFR1 and VEGFR2, and is the only member
of the VEGF gene family found to be induced by hypoxia
[14]. VEGF-B selectively binds VEGFR1 and has a role in
the regulation of extracellular matrix degradation and cell
adhesion and migration. Both VEGF-C and VEGF-D bind
VEGFR2 and VEGFR3 and regulate lymphangiogenesis, but
VEGF-C can also be found involved in wound healing [15].
PlGF selectively binds VEGFR1 and is the most abundantly
expressed VEGF family member in endothelial cells. PlGF
may potentiate VEGF-A-induced endothelial cell prolifera-
tion, but on its own PlGF exerts only weak mitogenicity [14].
Alternative exon splicing of the human VEGF-A gene
results in at least four major biologically active isoforms,
containing 121, 165, 189, and 208 aminoacids (ﬁve more are
VEGF145,V E G F 162,V E G F 165b,V E G F 183, and VEGF206)[ 16].
VEGF165 isthepredominantisoforminthehumaneyeandis
a heparin-binding, homodimeric, 45-kDa glycoprotein that
issecreted,althoughasubstantialfractionisboundtothecell
surface and to the extracellular matrix. Both VEGF189 and
VEGF208 are strongly heparin-binding and are sequestered in
the extracellular matrix. VEGF121 does not bind heparin and
is secreted. VEGF165 appears to be the isoform responsible
for pathological ocular neovascularization [17–19]. VEGF121
appears to be essential for normal retinal vascular function.
All VEGF-A isoforms except VEGF121 contain a plasmin
cleavage site and theoretically may be cleaved by plasmin to
generate the smaller VEGF110 form [16, 20].
The properties of VEGF can be summarized as follows:
[2, 21, 22]
(1) stimulator of angiogenesis;
(2) potent inducer of vascular permeability and fenestra-
tion;
(3) proinﬂammatory agent;
(4) neuroprotective agent;
(5) in neurodegenerative studies, displays neuroprotec-
tive eﬀects under conditions of hypoxia, oxidative
stress, and serum deprivation;
(6) in an in vitro model of cerebral ischemia, reduces cell
death;
(7) in vitro, protects hippocampal, cortical, cerebellar
granule, dopaminergic, autonomic, and sensory neu-
rons;
( 8 )v e s s e ls u r v i v a lf a c t o r .
More extensively, we can comment that VEGF acts
through various pathways which results in promoting patho-
logic neovascularization. It stimulates angiogenesis by being
a potent endothelial cell mitogen and sustains endothelial
survival by inhibiting apoptosis. In addition, VEGF is a
chemoattractant for endothelial cell precursors, including
their mobilization from the bone marrow and promoting
their diﬀerentiation. Bone-marrow-derived endothelial cell
precursors recruited in response to adenoviral-expressed
VEGF165 are necessary and suﬃcient for tumor angiogenesis
and are capable of inducing choroidal neovascularization
( C N V )i nm o u s em o d e l s .I ti sap o w e r f u la g o n i s to fv a s -
cular permeability which is particularly important in CNV.
Increased vascular permeability in response to VEGF may
be due to formation of fenestrations in microvascular endo-
thelium.
LeukocytesmayamplifytheeﬀectsofVEGFviatheirown
secretion of VEGF. Furthermore, VEGF’s proinﬂammatory
activity,predominantlythroughthe164isoform,contributes
to pathological ocular neovascularization.
VEGF has neuroprotective properties [23] that may be
attributed in part to its ability to increase the survival of
neurons and proliferating Schwann cells [24]. In rat models
when administered intravitreally, it displayed a protective
eﬀect on apoptotic retinal cells in a dose-dependant manner.
This protective eﬀect was inhibited by blockade of all VEGF
isoforms but not by blocade of VEGF164 alone.
VEGF causes angiogenesis by indirect mechanisms too.
Endothelial cell expression of metalloproteinases, which
degrade the extracellular matrix and facilitate tissue invasion
by new vessels, is upregulated by VEGF. Concurrently,
endothelial cell expression of tissue inhibitors of metallo-
proteinases is downregulated in response to VEGF, which
facilitates coordination of the angiogenic process. Also,
VEGF increases the expression endothelial nitric oxide [25]
synthase, which is an important mediator of VEGF-induced
endothelial cell proliferation.
The central role of VEGF-A is well established in ocular
neovascular diseases [26–30]. High levels of VEGF-A ex-
pression are found in CNV tissue excised from patients
with age-related macular degeneration (AMD). Intraocular
VEGF-A levels correlate with blood vessel formation in
patients with diabetic retinopathy and other retinal disorders
[31–33].
Diﬀerent VEGF-A isoforms may have diﬀerent functions
in ocular diseases. VEGF164 is the predominant isoform
expressed at the time of maximal preretinal neovasculariza-
tion in a neonatal rat model and is the primary proinﬂam-
matory isoform in the retina of rats with diabetes. Levels
of both VEGF121 and VEGF165 are increased in monkeys
after laser-induced retinal vein occlusion. VEGF120 is the
main isoform expressed in mouse CNV membranes, and
inhibition of VEGF120 results in reduction of CNV in mice.
Both VEGF121 and VEGF165 isoforms are found in CNVJournal of Ophthalmology 3
tissue excised from patients with AMD. Also, it seems that
VEGF levels, in rat models, increased in direct proportion to
the degree of neovascularization.
In studies of autopsy eyes, VEGF levels were found to
be elevated in the retinal pigment epithelium (RPE) and
choroidal blood vessels of macula with AMD [26, 30, 34].
The RPE is believed to play a key role in regulating
VEGFlevels.Inischemicretinaldisorders,VEGFsecretionby
culturedRPEwasfoundtobestrikinglyincreasedbyhypoxia
[2, 35].
Thus, we conclude that experimental elevation of VEGF
levels leads to ocular neovascularization and that inhibition
of VEGF action can prevent the development of ocular
neovascularization.
Preclinical studies have conﬁrmed that increased expres-
sion of VEGF is both necessary and suﬃcient for inducing
neovascularization, and several studies have provided evi-
dence that speciﬁc inhibition of VEGF can inhibit neovas-
cularization in the iris, choroid, cornea, and retina [36–38].
3. Anti-VEGFAgents
Inhibiting the activity of VEGF is believed to be an essential
treatment strategy for many forms of ocular neovascular-
ization [39]. Currently, mainly 3 anti-VEGF agents are in
clinical use; ranibizumab (Lucentis), pegaptanib sodium
(Macugen), and bevacizumab (Avastin) [1, 2].
At this point, it must be noted that AMD is the leading
cause of irreversible, severe loss of vision in people over
the age of 50 in the developed world, and it remains an
area of unmet medical need. The neovascular form of the
disease represents approximately 10% of the overall disease
prevalence, but it is responsible for 90% of the severe vision
loss [40].
Neovascular AMD is characterized by CNV that invades
the subretinal space, often leading to exudation and hem-
orrhage. If the condition is remained untreated, damage to
the photoreceptors and loss of central vision [41] usually
results, and after several months to years, the vessels are
largely replaced by a ﬁbrovascular scar. Patients in whom a
central scotoma develops have diﬃculty performing critical
tasks that are typically associated with central vision, such
as reading, driving, walking, and recognizing faces, and the
diﬃculty has a major eﬀect on their quality of life [42]. Thus,
we can understand that the introduction of the anti-VEGF
agents is a true revolution [43].
Pegaptanib sodium (Macugen), ﬁrst approved in the
United States for the treatment of neovascular AMD in 2004,
is a 28-base ribonucleic acid aptamer covalently linked to
two branched 20-kD polyethylene glycol moieties, that was
developed to bind and block the activity of extracellular
VEGF,speciﬁcallyatthe165-amino-acidisoform(VEGF165).
Ranibizumab (Lucentis) is a fragment of a recombinant,
humanized, monoclonal antibody Fab that binds to and
inhibits all the biologically active forms of vascular endothe-
lial growth factor A (VEGFA) [44].
Bevacizumab (Avastin) is an anti-VEGF full-length
antibody that initially was approved for the treatment of
metastatic cancer of the colon or rectum. It is used as a
possible oﬀ-label, safe alternative choice of lower cost [45].
It is the paternal molecule of ranibizumab.
These agents are administered intravitreally pars plana
[46–48].
4.Ranibizumab(Lucentis)
FDA has approved the use of ranibizumab as a treatment
for all the angiographic subtypes of the subfoveal neovas-
cularization of AMD. In clinical studies of phases I and II
ranibizumab has shown encouraging results of biological
activity with acceptable safety when it was administered
intravitreously for six months to patients suﬀering from
neovascuclar type of AMD.
In phase III trial MARINA [44], patients suﬀering from
neovascular type AMD were randomly assigned into 3
groups in a 1:1:1 ratio, receiving ranibizumab at a dose of
either 0.3mg or 0.5mg or a sham injection monthly (within
23 to 37 days) for two years (24 injections) in one eye.
The results were encouraging. After twelve months of
treatment, the 94.5% of the patients receiving 0.3mg and
94.6% of those receiving 0.5mg every month had lost fewer
than 15 letters ETDRS from baseline visual acuity. In the
shaminjectiongroupthepercentagedroppedsigniﬁcantlyto
the level of 62.2%. At 24 months, this end point was met by
92.0% of the patients receiving 0.3mg of ranibizumab and
90.0% of those receiving 0.5mg, as compared with 52.9% in
theshaminjectiongroup.Thevisualacuitybeneﬁtassociated
with ranibizumab was independent of the size of the baseline
lesion, the lesion type, or baseline acuity.
At 12 and 24 months, approximately 25% of patients
treated with 0.3mg of ranibizumab and 33% of patients
treated with 0.5mg of ranibizumab had gained 15 or more
letters in visual acuity, as compared to 5% or less in the sham
injection group.
At both doses of ranibizumab, the mean improvement
from baseline in visual acuity scores was evident 7 days after
the ﬁrst injection, whereas mean visual acuity in the sham
injection group declined steadily over time at each monthly
assessment. At 12 months, mean increases in visual acuity
were 6.5 letters in the 0.3mg group and 7.2 letters in the
0.5mg group, as compared with a decrease of 10.4 letters
in the sham injection group the beneﬁt in visual acuity was
maintained at 24 months.
At baseline, the percentages of patients with 20/40 vision
orbetterweresimilaramongthethreegroups.At12months,
approximately 40% of patients receiving ranibizumab had
20/40 vision or better, as compared with 11.3% in the sham
injection group. At 24 months, of the patients receiving
ranibizumab, 34.5% of those in the 0.3mg group and 42.1%
in the 0.5mg group had at least 20/40 vision, whereas the
proportion in the sham injection group had dropped to
5.9%.
Respectively,bigdiﬀerenceswereobservedtothepatients
with baseline visual acuity 20/20 or better. After 12 months,
the percentages were 3.8% for the 0.3mg group, 7.9% for the
0.5mg group, and 0.4% for the sham injection group.4 Journal of Ophthalmology
Table 1: Ranibizumab-related adverse events followed 24-month study period.
Adverse Events at 24 months Sham injection Group 0.3mg Group 0.5mg
Endopnthalmitis 0% 0.8% 1.3%
Uveitis 0% 1.3% 1.3%
Rhegmatogenous retinal detachment 0.4% 0% 0%
Retinal tear 0% 0.4% 0.4%
Vitreous hemorrhage 0.8% 0.4% 0.4%
Lens damage 0% 0% 0.4%
Most severe ocular inﬂammation
none 87.3 83.2% 79.1%
trace 10.2 8.0% 14.6%
1+ 2.5% 5.9% 3.3%
2+ 0 0.8% 0.8%
3+ 0 0.8% 0.8%
4+ 0 1.3% 1.3%
Nonocular adverse events
Arterial hypertension 16.1 17.2% 16.3%
Myocardial infarction 1.7% 2.5% 1.3%
Stroke 0.8% 1.3% 2.5%
Non ocular hemorrhage 5.5% 9.2% 8.8%
The percentages of patients with visual acuity of 20/200
or worse were similar among the 3 groups at baseline. At 12
and 24 months, the percentages in the ranibizumab-treated
groups remained the same, whereas the percentages in the
sham injection group had increased by 3 to 3.5 times.
Very few patients receiving ranibizumab had severe loss
of vision (30 letters or more) from baseline whereas in the
sham injection group the percentages were 14.3% at 12
months and 22.7% at 24 months.
Cumulatedadverseeventsforthe24-month studyperiod
are summarized in Table 1 as well as the percentages of each
adverse event [44].
In conclusion, according to this phase III study, patients
treated with ranibizumab had beneﬁts. This study demon-
strated not only prevention of vision loss but also a mean
improvement, whereas patients in sham injection group
continued to decline. These beneﬁts are being achieved with
low-rate appearance of severe ocular adverse events. The rate
of the adverse events did not diﬀer much from the rates in
the sham injection group. The three treatment groups did
not clearly diﬀer in their rates of nonocular adverse events
too.
Similar results and beneﬁts for the patients suﬀering
neovascular type of AMD presented the PIER study [49].
In this study, ranibizumab was administered at doses of
0.3mg and 0.5mg for three months followed by a fourth
dose after a period of 3–12 months. On the same time, the
rate of adverse events or side eﬀects was low (both ocular
and nonocular). Approximately, the 90% of the treated
patients had lost fewer than 15 ETDRS letters compared
with 50% of the sham group. In addition, at 12 months
maintenance of visual acuity was accompanied on average
by a signiﬁcant reduction in vascular leakage, reduced foveal
retinal thickness, and inhibition of CNV lesion growth. This
initial impression is supported by individual OCT responses.
Although this study provided clinically meaningful and
statistically signiﬁcant beneﬁt to patients, the outcomes were
not as strong as those observed with monthly dosing of
ranibizumab, suggesting that some patients may require
dosing on a more frequent schedule such as that used
in the MARINA or ANCHOR studies. It is possible that
OCT-guided administration of ranibizumab retreatment, as
was used in a small, uncontrolled study, may allow greater
individualization of ranibizumab dose intervals [50].
Also it would be interesting to compare ranibizumab
with PDT treatment, a treatment modality frequently used
so far ANCHOR a multicenter, double-masked, phase III
trialcomparedpatient-reportedvisualfunctioninthosewith
neovascular age-related macular degeneration treated with
ranibizumab or verteporﬁn photodynamic therapy (PDT).
Patients were randomized 1:1:1 to verteporﬁn PDT plus
monthly sham intraocular injection or to sham verteporﬁn
PDT plus monthly intravitreal ranibizumab (0.3mg or
0.5mg) injection. The need for PDT (active or sham)
retreatment was evaluated every 3 months using ﬂuorescein
angiography (FA).
The conclusion of this study was that ranibizumab
provided greater clinical beneﬁt than verteporﬁn PDT in
patients with age-related macular degeneration with new-
onset, predominantly classic CNV. Rates of serious adverse
events were low [51, 52].
T h eS U M M I Ts t u d yg o e so n es t e pb e y o n da n dt r i e s
to compare the combined therapy of PDT ranibizumab
together versus ranibizumab alone. More speciﬁcally, SUM-
MIT is a clinical trial program that includes two similarly
designed, controlled studies to further examine the safety,
eﬃcacy, and treatment burden of combination therapy with
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comparedwithranibizumabalone:DENALIintheUSA,and
Canada, examining verteporﬁn PDT in combination at both
standard- and reduced-ﬂuence light doses; MONT BLANC
in Europe, examining verteporﬁn PDT in combination at
standard-ﬂuencelightdoseonly.Twelve-monthresultsofthe
MONTBLANCstudyshowthatcombiningstandard-ﬂuence
PDT with ranibizumab 0.5mg can deliver VA improvements
that are noninferior to a ranibizumab monotherapy regimen
with three ranibizumab-loading doses followed by injections
on a monthly as-needed basis (noninferiority margin of
7 letters). There was no signiﬁcant diﬀerence between
the combination and monotherapy groups with regard to
proportion of patients with a treatment-free interval of at
least three months duration after Month 2. There were no
unexpected safety ﬁndings, and adverse event incidence was
similar between treatment groups.
Twelve-month results of the DENALI study showed that
combining PDT with ranibizumab with three ranibizumab
loading doses followed by additional injections on a monthly
as-needed basis can improve visual acuity at month 12 in
patients with subfoveal choroidal neovascularization (CNV)
secondary to wet age-related macular degeneration (wet
AMD). At month 12, patients in the standard ﬂuence com-
bination group gained on average 5.3 letters from baseline
and patients in the reduced ﬂuence combination group
gained on average 4.4 letters. Patients in the ranibizumab
monthly monotherapy group gained on average 8.1 letters at
month 12. DENALI did not demonstrate non-inferior visual
acuity gain for PDT combination therapy compared with
ranibizumab monthly monotherapy.
Also some studies were conductedin order to check if the
individualizationofthetreatmentandthePreReNata(PRN)
(as needed) treatment especially under OCT guidance in
patientswithAMDcanhavethesameeﬃcacyandsafetywith
the standard monthly injections. The SUSTAIN study [53],
a twelve-month, phase III, multicenter, open-label, single-
arm study concluded that the safety results are comparable
to the favorable tolerability proﬁle of ranibizumab observed
in previous pivotal clinical studies; individualized treatment
with less than monthly retreatments shows a similar safety
proﬁle as observed in previous randomized clinical trials
with monthly ranibizumab treatment. Eﬃcacy outcomes
were achieved with a low average number of re-treatments.
Visual acuity in SUSTAIN patients with individualized
re-treatment based on VA/optical coherence tomography
assessment reached on average a maximum after the ﬁrst
3 monthly injections, decreased slightly under PRN during
the next 2 to 3 months and was then sustained through-
out the treatment period. Also PRONTO study [50], an
open-label, single-center prospective study using a variable
dosing regimen guided by optical coherence tomography
(OCT) concluded that intravitreal injection of ranibizumab
resulted in rapid improvements in visual acuity and OCT
measurements. After 12 and 24 months, outcomes in the
study were similar to the MARINA and ANCHOR phase
III study results but with the mean frequency of dosing
reduced by more than half, to about ﬁve injections per year.
Based on these results, OCT appears to be a useful tool for
guiding retreatment decisions for patients with neovascular
AMD. Furthermore, the CATT study [54] ,am u l t i c e n t e r ,
single-blind, noninferiority trial, at year 1 showed that rani-
bizumabgivenasneededwithmonthlyevaluationhadeﬀects
on vision that were equivalent to those of ranibizumab
administered monthly. Diﬀerences in rates of serious adverse
events require further study.
5.PegaptanibSodium(Macugen)
Similarly, studies were conducted for pegaptanib sodium
(Macugen) also. Diﬀerent trials under the supervision of
inhibition study in ocular neovascularization clinical trial
group (VISION) were conducted [47].
Patients with diﬀerent types of CNV were separated into
two groups. The ﬁrst group was receiving a sham injection
and the second one was receiving intravitreously an injection
of pegaptanib sodium into one eye per patient every six
weeks for a period of 48 weeks in total.
In these trials, patients were receiving pegaptanib at a
dose of 0.3mg, 1.0mg, 3.0mg, or sham injection.
In the combined analysis of the results of these trials
and the three diﬀerent doses of pegaptanib sodium, we
can observe a signiﬁcant diﬀerence between the patients
receiving treatment and those receiving a sham injection.
Pegaptanib sodium (Macugen) oﬀered a statistically
important and clinically essential beneﬁt in the treatment
of AMD. Declined risk for visual acuity loss observed to all
doses only six weeks after the initiation of the treatment,
the eﬀectiveness of pegaptanib increased over time up to
week 54, as measured by the mean loss of visual acuity
from baseline to each study visit compared with that in the
sham injection group. That is supported by many ﬁndings.
Pegaptanib sodium reduced the risk not only of the visually
acuityloss≥15ETDRSletters(consideredasanaverageloss),
but also of a loss ≥30 letters (considered as a severe loss).
In addition, treatment with pegaptanib reduced the risk of
progression to legal blindness, promoted stability of vision
and in a small percentage of patients, resulted in more visual
improvement at week 54 than among those receiving sham
injections.
The visual results are further supported by angiographic
measurements which suggested a reduction in the growth
of the total size of the lesion or of CNV and in the
severity of leakage. Also it causes reduction of the vascular
permeability, factor that seems to have an important role in
the improved visual outcomes observed. Because all forms of
CNV have been associated with elevated levels of VEGF, it is
hypothesizedthatabroadspectrumofpatientsmightbeneﬁt
with anti-VEGF therapy with pegaptanib sodium.
Most adverse events reported in the study eyes were tran-
sient, with a severity that was mild to moderate. Common
ocular adverse events that occurred more frequently in the
study eyes of patients treated with pegaptanib than in those
receiving sham injection were eye pain (34% versus 28%),
vitreous ﬂoaters (33% versus 8%), punctuate keratitis (32%
versus 27%), cataracts (20% versus 18%), vitreous opacities
(18% versus 10%), anterior chamber inﬂammation (14%
versus 6%), visual disturbance (13% versus 11%), eye dis-
charge(9%versus8%),andcornealedema(10%versus7%).6 Journal of Ophthalmology
The perinjection rates of adverse events were endoph-
thalmitis (0.16%), retinal detachment (0.08%), and trau-
matic lens injury (0.07%), rates that were similar to the ones
intheshaminjectiongroup.Theriskofendophthalmitis was
1.3% per patient after one year of treatment.
Furthermore, there were no ﬁndings in relation to vital
signs performed at each clinical assessment or ECG test
results that were suggestive of a relationship to treatment
withpegaptanib sodium; in particular, therewasno evidence
of an increase in mean blood pressure over the 3 years
of treatment. The types and incidence of systemic serious
adverse events observed are not unexpected in this elderly
patientpopulation,andnoneoftheseeventswasjudgedtobe
related to study drug. This favourable systemic safety proﬁle
is of particular importance for this population, that is, at
higher risk for cardiovascular and thromboembolic diseases
[55].
In order to maximize the beneﬁt of the treatment, it is
critical that all treating ophthalmologists carefully adhere to
an appropriate aseptic technique for each injection, educate
patients regarding worrying symptoms, and closely monitor
patients—after each injection.
Similar results were achieved in vitro and in studies to
animals.
Pegaptanib sodium was the ﬁrst anti-VEGF agent ap-
proved for intravitreal administration for neovascular AMD.
The VA results of the VISION study are clearly inferior
to those of the MARINA and ANCHOR studies with
ranibizumab. At the time of writing, therefore, pegaptanib
sodium is considered second-line therapy. However, VA
eﬃcacy is only one of the clinical considerations that must
be taken into account. Also the safety proﬁle of the agent
both in VISION study and in a german study [56] was good;
VISION’s safety proﬁle was described earlier, and in the
german study no relevant systemic or ocular side eﬀects were
noted. Cardiovascular incidents and overall mortality in the
pegaptanib sodium group were comparable to those of the
sham injection group. In addition, a separate trial looking
at intravitreal pegaptanib sodium injections over a 2-year
periodconcludedthattherewasnoclinical-orangiographic-
proven retinal or choroidal damage detectable. Thus, we
understand that pegaptanib is a relatively safe choice that
improves vision and must under consideration especially
when the candidate of anti-VEGF treatment suﬀers from
cardiovascular diseases.
In conclusion, pegaptanib sodium oﬀers, statically and
clinically, a meaningful beneﬁt to the patients suﬀering from
AMD, regardless of the size or angiographic subtype of the
lesion or the baseline visual acuity [1, 2, 40–50].
6.Bevacizumab(Avastin)
Bevacizumab is the father molecule of ranibizumab, and it
is administered intravitreously as an oﬀ-label choice, since
its original use is intravenous to colon and rectum cancers.
Small study [39] by Ciulla and Rosenfeld has demonstrated
beneﬁts and results, for the patients suﬀering from AMD,
similar to those of ranibizumab. Its rather smaller cost,
consists a plus for using bevacizumab as treating agent [1,
2, 40–50].
7.Bevacizumab-RanibizumabRelation
Due to the close molecular relation between bevacizumab
(Avastin) and ranibizumab, a comparison between these two
anti-VEGF agents would have been very interesting [54].
Alsothelackofalarge-scaleclinicaltrialdata(thesmallstudy
byCiullaandRosenfeld)andthefactthatintheUnitedStates
bevacizumab is the most commonly used anti-VEGF agent
by the ophthalmologists as an oﬀ-label, low cost alternative
treatment,suggeststhecomparisonbetweenthemevenmore
necessary. This gap was recently ﬁlled by ranibizumab and
bevacizumab for age-related macular degeneration study of
the CATT research group.
The purpose of this study was to assess the relative
eﬃcacy and safety of ranibizumab and bevacizumab and to
determine whether an as-needed regimen would compro-
mise long-term visual acuity, as compared with a monthly
regimen.
Patients were randomly assigned to four groups after
the ﬁrst mandatory intravitreal injection: ranibizumab every
28 days (ranibizumab monthly), bevacizumab every 28
days (bevacizumab monthly), ranibizumab only when signs
of active neovascularization were present (ranibizumab
as needed), and bevacizumab only when signs of active
neovascularization were present (bevacizumab as needed).
The dose was 0.5mg (in 0.05mi of solution) for ranibi-
zumab and 1.25mg (in 0.05mL of solution) for bevaci-
zumab. The commercially acquired bevacizumab had to be
repackaged in glass vials in an aseptic ﬁlling facility.
Every 28 days, patients in the groups that received study
drugs as needed underwent time-domain OCT and were
evaluated for treatment. Also ﬂuorescein angiography was
performed at the discretion of the ophthalmologists in order
to aid in retreatment decisions.
According to this study, visual acuity improved from
baseline to 1 year in all four study groups. Most of the im-
provement occurred during the ﬁrst six months. At 1 year,
bevacizumab was equivalent to ranibizumab, both when
the drugs were administered monthly and when the drugs
were given as needed. Ranibizumab given as needed was
equivalent to bevacizumab given monthly. The comparison
between bevacizumab given as needed and ranibizumab
given monthly was inconclusive, and so was the comparison
between bevacizumab given as needed and bevacizumab
given monthly.
The outcomes for the pairwise comparisons between
study groups did not change after the clinical adjustment for
clinical center, age, baseline lesion size.
At 1 year, the proportion of patients who did not have a
decrease in visual acuity of 15 letters or more from baseline
was 94.4% in the ranibizumab-monthly group, 94.0% in
thebevacizumab-monthlygroup,95.4%intheranibizumab-
as-needed group, and 91.5% in the bevacizumab-as-needed
group. The proportion of patients who gained at least 15
letters increased during the ﬁrst 36 weeks in all four studyJournal of Ophthalmology 7
groupsat1yeardidnotdiﬀersigniﬁcantly,rangingfrom24.9
to 34.2%.
The two drugs resulted in a substantial reduction in
total retinal thickness at the fovea after the ﬁrst injection.
At four weeks, no ﬂuid was detected on OCT for 27.5%
of the patients treated with ranibizumab and 17.3% for
patients treated with bevacizumab. At 1 year the proportion
of patients with no ﬂuid on OCT ranged from 19.2% among
patients who received bevacizumab as needed to 43.7%
among those who received ranibizumab monthly.
Dye leakage was absent on angiography in 58.8% of
patients in the ranibizumab-monthly group, 57.7% in the
bevacizumab-monthly group, 46.7% in the ranibizumab-
as-needed group, and 41% in the bevacizumab-as-needed
group.
However, the lesions size on angiography were slightly
larger in the two groups treated as needed.
The ocular adverse events were endophthalmitis (0.7%
for ranibizumab monthly group and 1.4 for bevacizumab
monthly group) and uveitis, retinal detachment, ocular-
vessel occlusion or embolism, retinal tear, vitreous hemor-
rhage that each of them occurred in less than 1% of the
patients.
The serious systemic adverse events included arterio-
thrombotic events with a similar percentageof 2-3% foreach
group, venous thrombotic events in approximately 1.0% of
the patients. One or more serious systemic adverse events
occurred in 21.5% of patients in total, the percentages,
respectively, for each group were 17.6% in the ranibizumab-
monthly group, 22.4% in the bevacizumab-monthly group,
20.5% in the ranibizumab-as-needed group, and 25.7% in
the bevacizumab-as-needed group.
Other serious systemic adverse events with similar rates
for group were cardiac disorder (3.3% to 5.6%), infection
(2.0% to 6.0%), nervous system disorder (2.0% to 4.0%),
injury or procedural complication (2.3% to 3.8%), benign
or malignant neoplasm (1.7% to 3.4%), surgical or medical
procedure (1.3% to 2.7%), and gastrointestinal disorder
(0.7% to 3.0%).
The comparison between the two drugs shown that these
two anti-VEGF agents had equivalent eﬀects on visual acuity
at time points throughout the ﬁrst year of followup. The
mean number of letters gained the proportion of patients in
whomvisualacuitywasmaintained(<15letterslost),andthe
proportion of patients who had a gain of at least 15 letters
were nearly the same for each drug, when regimen was the
same.
Also excellent results for visual acuity could be achieved
with less than monthly regimens for both drugs. The mean
number of letters gained were 5.9 letters with bevacizumab
given as needed, 6.8 letters with ranibizumab given as
needed,8.5letterswithranibizumab-monthly,and8.0letters
with bevacizumab-monthly.
Both bevacizumab and ranibizumab substantially and
immediately reduced the amount of ﬂuid in or under
the retina. The proportion of patients who had complete
resolution of ﬂuid was greater with ranibizumab than with
bevacizumab.Thisdiﬀerencewasevidentafterﬁrstinjection,
with no ﬂuid seen at 4 weeks in 27.5% of patients receiving
ranibizumab and 17.3% of those receiving bevacizumab, and
the diﬀerence persisted throughout the year. Furthermore,
the absolute between drug diﬀerences in the amount of
residual ﬂuid was small, and in the majority of patients
neither drug eliminated all ﬂuid.
Themeandecreaseincentralretinalthicknesswasgreater
in the ranibizumab-monthly group (196μm) than in the
other groups (152 to 168μm).
Monthly injections of either drug resulted in no increase
in the mean lesion area, whereas there was a small increase
when injections were given as needed.
The rates of both ocular and nonocular adverse events
were similar. However, the rate of serious systemic adverse
events and primarily hospitalizations was higher among
bevacizumab-treated patients than among ranibizumab-
treated patients (24.1% versus 19.1%). But at this point it
should be noted that the median age of patients in the CATT
Study was over 80 years, and a high rate of hospitalizations
might be anticipated as a result of chronic or acute medical
conditions more common to older populations.
After the head to head comparison between the two
agentsaccordingtothis study, weobserve similartherapeutic
results and adverse events. The factor that was signiﬁcantly
diﬀerent was the average cost of drug per patient. It was
23,400USDinranibizumab-monthlygroupand13,800USD
in ranibizumab as-needed group while in the bevacizumab
groups it was 595 USD and 385 USD in bevacizumab-
monthly and bevacizumab as needed, respectively. Previ-
ously it was mentioned that AMD is the leading cause of
irreversible, severe loss of vision of people about 55 years of
ageorolderthusresultinginabignumberofpatients.Sothis
signiﬁcantdiﬀerenceoftreatmentcostmustgounderserious
consideration [57].
8. VEGF-TRAP
VEGF-Trap is a novel anti-VEGF drug. It is a receptor decoy
that functions by literally trapping VEGF. It is a recombinant
chimeric molecule that contains the VEGF-binding elements
from the extracellular domains of VEGF receptors 1 and 2
fused to the Fc portion of human IgG. It binds all VEGFA
isoforms and placental growth factor with high aﬃnity [58].
In several mouse models, VEGF-Trap was shown to
partially suppress CNV when injected either subcutaneously
(systemically) or intravitreally. It decreased the area of CNV
in a mouse model of laser-induced CNV. It also decreased
the area of CNV in transgenic mice that express VEGF in the
photoreceptors. Subcutaneous injection of VEGF-TRAP led
to a reduction in retinal vascular permeability in mice whose
retinas were exposed to VEGF.
Both aﬂibercept (the oncology product) and VEGF
Trap-Eye are manufactured in bioreactors from industry
standard Chinese hamster ovary cells that overexpress the
fusion protein. However, VEGF Trap-Eye undergoes further
puriﬁcation steps during manufacturing to minimize risk of
irritation to the eye. The highest intravitreal dose being used
in pivotal trials for VEGF Trap-Eye is 2mg/month [58].
The safety, tolerability, and biological activity of intravit-
real VEGF Trap-Eye in treatment of neovascular AMD was8 Journal of Ophthalmology
evaluated in the two-part Clinical Evaluation of Antian-
giogenesis in the Retina-1 (CLEAR-IT-1) [59]s t u d y .T h e
ﬁrst part was a sequential cohort dose-escalation study in
which 21 patients were monitored for safety, changes in
fovealthicknessonOCT,bestcorrectedvisualacuity(BCVA)
and lesion size on FA for 6 weeks. No adverse systemic or
oculareventswerenotedandvisualacuityremainedstableor
improved ≥3linesin95%ofpatientswithameanincreasein
BCVA of 4.6 letters at 6 weeks. Patients showed substantially
decreased foveal thickness.
In the second part, patients received a single intravitreal
injection of either 0.5 or 4mg of VEGF Trap-Eye and were
followedfor8weeks.At8weeks,themeandecreaseinretinal
thickness in the low-dose group was 63.7μmc o m p a r e dt o
175μm for the high-dose group.
CLEAR-IT-2 trial was a prospective, randomized, multi-
center, and controlled dose- and interval-ranging Phase II
trial in which 157 patients were randomized to ﬁve-dose
groups and treated with VEGF Trap-Eye in one eye. Two
groups received monthly doses of either 0.5 or 2.0mg for 12
weeks (at weeks 0, 4, 8, and 12) and three groups received
quarterly doses of either 0.5, 2.0, or 4.0mg for 12 weeks
(at weeks 0 and 12). Following this ﬁxed dosing period,
patients were treated with the same dose of VEGF Trap-Eye.
Patientsinitiallytreatedwith2.0or0.5mgofVEGFTrap-Eye
monthlyachievedmeanimprovementsof9.0and5.4ETDRS
letters with 29 and 19% gaining, respectively, ≥15 ETDRS
letters at 52 weeks. Patients in these two monthly-dosing
groups also displayed mean decreases in retinal thickness
versus baseline of 143μm in the 2.0mg group and 125μm
in the 0.5mg group at 52 weeks as measured by OCT.
Patients in the three quarterly dosing groups also showed
meanimprovementsinBCVAandretinalthickness;however,
they were generally not as profound as the monthly injection
group.
In phase III studies’ VIEW 1 (conducted in USA and
Canada) and VIEW 2 (Europe, Asia paciﬁc, Latin America,
and Japan) VEGF Trap-Eye was evaluated for its eﬀect
on maintaining and improving vision when dosed as an
intravitreal injection on a schedule of 0.5mg monthly,
2mg monthly, or 2mg every two months (following three
monthly loading doses), as compared with intravitreal
ranibizumab administered 0.5mg every month during the
ﬁrst year of the studies. As-needed dosing with both agents,
with a dose administered at least every three months (but
not more often than monthly), is being evaluated during the
second year of each study.
The results for the primary and the ﬁrst secondary
endpoint prespeciﬁed for testing concerning both the main-
tenance(lossof15lettersorless)andthemeanimprovement
invisionatweek52versusbaselinearepromisingandsimilar
at all groups. The percentages for maintenance are ranging
from 94.4% to 96.3%, and the mean improvement is ranging
from 6.9 to 10.9 letters.
Based on Phase II study data, VEGF Trap-Eye seems
to be generally well tolerated with no serious drug-related
adverse events. The most common adverse events reported
in the study included conjunctival hemorrhage (38.2%),
transient increased intraocular pressure (18.5%), refraction
disorder (15.9%), retinal hemorrhage (14.6%), subjective
visualacuityloss(13.4%),vitreousdetachment(11.5%),and
eye pain (9.6%) [60].
9. RNA Interference
SIRNAstandsforshortinterferingRNA.SIRNAsare21to25
nucleotide-long double-stranded RNA molecules capable of
destroying a corresponding target messenger RNA with high
selectivity and eﬃcacy [61]. This leads to posttranscriptional
gene silencing (PTGS).
SIRNAs work intracellular where they are incorporated
into a protein complex called RNA-induced silencing com-
plex (RISC) [61]. The RISC has RNA helicase activity, which
unwinds the two strands of RNA starting by the terminus
with the lowest melting temperature (highest A-U base
pairs).
The strand of the siRNA that becomes associated to the
RISC leads the complex to selectively cleave and degrade
messenger RNA molecules containing a complementary
sequence. The siRNA is engineered to match the protein
encoding nucleotide sequence of the target messenger RNA.
Since the translation of messenger RNA into proteins is an
ampliﬁcationstepwherebyasinglemessengerRNAmolecule
canleadtotheproductionofaround5.000copiesofaprotein
molecule, destroying the messenger RNA is a very potent
method of inhibiting protein function.
SIRNA-027 (SIRNA Therapeutics, Inc.) is a short inter-
fering RNA that targets the VEGF receptor 1 (VEGFR-1).
VEGFR-1 is found primarily on vascular endothelial cells
and is stimulated by both VEGF and placental growth
factor (PlGF), resulting in the growth of new blood vessels.
Animal experiments have shown that both intravitreous and
periocular injections of siRNA directed against VEGFR1 lead
to a substantial reduction of VEGFR1 messenger RNA levels.
The siRNA suppressed the development of CNV at rupture
sitesinBruch’smembraneanddecreasedretinalneovascular-
ization in mice with oxygen-induced ischemic retinopathy.
These data suggest that VEGFR1 plays an important role in
the development of ocular neovascularization [62, 63].
AcuityPharmaceuticalshasalsoproducedasiRNAcalled
Cand5 or Bevasiranib that targets the messenger RNA of the
VEGF protein itself. Animal models have shown prevention
of CNV after laser-induced injury.
Bevasiranib sodium was developed for intravitreal
administration and, like other intravitreal antiangiogenic
agents, requires knowledge of specialized injection tech-
niques. Following intravitreal injection, bevasiranib is well
distributed within the eye and localizes to the retina [64, 65].
Preliminary results of Phases I and II clinical trials of
bevasiranib have shown promising results for the treatment
of wet AMD and diabetic macular edema.
T h e r ea r ev a r i o u ss t u d i e so fd i ﬀerent phases underway
(but COBALT study is terminated). A phase III study
evaluating the combination of bevasiranib and ranibizumab
in wet AMD (the CARBON study) is currently under-
way. The purpose of this study is to compare intravitreal
bevasiranib sodium as maintenance therapy for AMD fol-
lowing initiation of anti-VEGF therapy with three dosesJournal of Ophthalmology 9
of ranibizumab. Preliminary clinical results indicate that
the eﬀects of bevasiranib do not appear until six weeks
after the commencement of treatment, which suggests that
combination therapy when using bevasiranib as an adjunct
might be justiﬁed. The notion that the eﬀect of bevasiranib is
appearing late might be linked to its mechanism of action,
since bevasiranib inhibits the synthesis of new VEGF, and
does not eliminate existing VEGF, a direct anti-VEGF agent
may be required to neutralize VEGF already present in the
eye before the eﬀects of inhibiting new VEGF synthesis
are realized. Preliminary results of the carbon and cobalt
studies suggested that over 30% of patients on combination
ranibizumab-bevasiranib achieve at least three more lines of
visual acuity than those on ranibizumab alone. The safety
and eﬃcacy of this combination awaits the full results of the
ongoing clinical trials.
Although the safety proﬁles and eﬃcacy results of clinical
trials are promising, the lack of available data from ran-
domized placebo-controlled or comparative studies makes it
diﬃcult to objectively evaluate the role of bevasiranib in wet
AMD therapy. It is clear from experimental and preclinical
studies that anti-VEGF siRNA (either bevasiranib or simi-
lar formulations) technology is capable of downregulating
VEGF production, a key goal of anti-VEGF therapy [66].
In summary, bevasiranib exploits an interesting technol-
ogy [66, 67] and may be a useful addition to the currently
available drugs used to treat wet AMD.
10. Anti-VEGFand MacularEdema
The DA VINCI study, a phase II study, tries to determine
whether diﬀerent doses and dosing regimens of intravitreal
vascular endothelial growth factor (VEGF) Trap-Eye are
superior to focal/grid photocoagulation in eyes with diabetic
macular edema (DME). Patients were assigned to 1 of 5
treatment regimens: 0.5mg VEGF Trap-Eye every 4 weeks;
2mg VEGF Trap-Eye every 4 weeks, 2mg VEGF Trap-Eye
for 3 initial monthly doses and then every 8 weeks, 2mg
VEGF Trap-Eye for 3 initial monthly doses and then on an
as-needed (PRN) basis, or macular laser photocoagulation.
Assessments were completed at baseline and every 4 weeks
thereafter. The main outcome measures were the mean
change in visual acuity and central retinal thickness (CRT)
at 24 weeks.
The primary results showed that intravitreal VEGF Trap-
Eye produced a statistically signiﬁcant and clinically relevant
improvement in visual acuity when compared with macular
laser photocoagulation in patients with DME.
In detail, patients in the 4 VEGF Trap-Eye groups
experienced mean visual acuity beneﬁts ranging from +8.5
to +11.4 Early Treatment of Diabetic Retinopathy study
(ETDRS) letters versus only +2.5 letters in the laser group
(P ≤ 0.0085 for each VEGF Trap-Eye group versus laser).
Gains from baseline of 0+, 10+, and 15+ letters were seen in
up to 93%, 64%, and 34% of VEGF Trap-Eye groups versus
up to 68%, 32%, and 21% in the laser group, respectively.
Mean reductions in CRT in the 4 VEGF Trap-Eye groups
ranged from −127.3 to −194.5μm compared with only
−67.9μm in the laser group (P = 0.0066 for each VEGF
Trap-Eye group versus laser). VEGF Trap-Eye was generally
well tolerated. Ocular adverse events in patients treated with
VEGF Trap-Eye were generally consistent with those seen
with other intravitreal anti-VEGF agents [68].
Also another phase II controlled clinical trial by Senger
et al. [3] and Cunningham et al. [69] showed a considerably
higher rate of visual gain of ≥10 letters of visual acuity for
pegaptanib-treated patients compared with sham-injected
patients(34%versus10%)forpatientswithdiabeticmacular
edema. The conclusion of this trial was that subjects assigned
to pegaptanib had better VA outcomes, were more likely to
showreductionincentralretinalthickness,andweredeemed
less likely to need additional therapy with photocoagulation
at followup.
Also smaller studies show that the intravitreal use of
bevacizumab can be a safe alternative treatment and a
promising option for patients suﬀering from DME [70, 71].
11. Conclusions
Numerous clinical trials are undergone to examine the
comparative eﬃcacy and safety of these anti-VEGF agents.
While these studies may not detect clinical superiority of
one agent over the over, larger prospective randomized trials
will reassure their safety and conﬁrm their eﬃcacy in the
future. Anti-VEGF agents are now under evaluation for
other diseases such as pathologic myopia, angioid streaks,
idiopathic polypoidal choroidal vasculopathy, and ocular
histoplasmosis.
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